Oral vs Intravenous Antibiotics for Fracture-Related Infections: The POvIV Randomized Clinical Trial.

Journal: JAMA Surgery
Published:
Abstract

Fracture-related infection (FRI) is a serious complication following fracture fixation surgery. Current treatment of FRIs entails debridement and 6 weeks of intravenous (IV) antibiotics. Lab data and retrospective clinical studies support use of oral antibiotics, which are less expensive and may have fewer complications than IV antibiotics. To evaluate the effectiveness of treatment of FRI with oral vs IV antibiotics. The POvIV multicenter, prospective randomized clinical trial was conducted across 24 trauma centers in the US among patients aged 18 to 84 years who had fracture repair or arthrodesis with fixation with implants and developed an FRI without radiographic evidence of osteomyelitis. Patients were enrolled between March 2013 and September 2018 and followed up for 12 months after hospitalization for treatment of their FRI. Oral vs IV antibiotics following FRI. The primary outcome was number of surgical interventions, and the primary hypothesis was noninferiority of oral vs IV antibiotics with respect to the number of study injury-related surgical interventions by 1 year. Unadjusted modified intent-to-treat (mITT) and adjusted per-protocol (PP) analyses were prespecified. A post hoc adjusted mITT analysis was conducted to resolve discrepancies between the results of the prespecified mITT and PP analyses. Recurrence of a deep surgical site infection was a key secondary outcome. Among 233 total patients, mean (SD) age was 46.0 (13.9) years, and 53 patients were female (22.7%). The mean number of surgical interventions within 1 year was 1.3 and 1.1 for the oral and IV groups, respectively. The upper bound of the 95% confidence interval of the mean difference with unadjusted mITT analysis was 0.59, which was lower than the prespecified noninferiority margin of 0.67, indicating noninferiority of oral to IV antibiotics. Adjusted PP analysis did not support noninferiority of the number of reoperations. A post hoc adjusted mITT analysis also showed noninferiority. The treatment effects estimates for the key secondary outcome of reinfection showed a similar pattern as those for the primary outcome. In this prospective randomized clinical trial, oral antibiotic treatment was noninferior to IV treatment with respect to the primary outcome of number of surgical interventions based on mITT analysis. However, there is some uncertainty in these findings based on preplanned and post hoc secondary analyses. A similar pattern of treatment effect estimates was observed for the secondary outcome of recurrence of infection. ClinicalTrials.gov Identifier: NCT01714596.

Authors
Robert O'toole, Saam Morshed, Paul Tornetta, Clinton Murray, Clifford Jones, Daniel Scharfstein, Tara Taylor, Anthony Carlini, Jennifer Desanto, Renan Castillo, Michael Bosse, Madhav Karunakar, Rachel Seymour, Stephen Sims, David Weinrib, Christine Churchill, Eben Carroll, Holly Pilson, James Goodman, Martha Holden, Anna Miller, Debra Sietsema, Philip Stahel, Hassan Mir, Andrew Schmidt, Jerald Westberg, Brian Mullis, Karl Shively, Robert Hymes, Sanjit Konda, Heather Vallier, Mary Breslin, Christopher Smith, Colin Crickard, J Reid, Mitch Baker, W Eglseder, Christopher Lebrun, Theodore Manson, Daniel Mascarenhas, Jason Nascone, Andrew Pollak, Michael Schloss, Marcus Sciadini, Yasmin Degani, Theodore Miclau, David Weiss, Seth Yarboro, Eric Mcvey, Reza Firoozabadi, Julie Agel, Eduardo Burgos, Vamshi Gajari, Andres Rodriguez Buitrago, Rajesh Tummuru, Karen Trochez